GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3318 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
- Conditions
- Streptococcal Infections
- Interventions
- Biological: Low dose Strep A AlumBiological: Medium dose Strep A AlumBiological: High dose Strep A AlumBiological: Low dose Strep A AS37Biological: Medium dose Strep A AS37Biological: High dose Strep A AS37Drug: Strep A Alum Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 108
- Registration Number
- NCT07085702
- Locations
- 🇦🇺
GSK Investigational Site, Camberwell, Victoria, Australia
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 106
- Registration Number
- NCT07084896
- Locations
- 🇺🇸
238995, Atlanta, Georgia, United States
🇺🇸240593, Boston, Massachusetts, United States
🇺🇸251164, Grand Rapids, Michigan, United States
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
- Conditions
- Malaria
- Interventions
- Biological: RTS,S/AS01E vaccine
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 238
- Registration Number
- NCT07036159
- Locations
- 🇷🇼
Center for Family Health Research, Kigali, Rwanda
🇷🇼Rinda Ubuzima Gatenga Medicalized Health Center University of Rwanda, Kigali, Rwanda
A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)
- Conditions
- Meningitis
- Interventions
- Biological: rMenB+OMV NZ vaccine
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT06995430
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- Conditions
- Neoplasms, Prostate
- Interventions
- Drug: GSK5458514
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 82
- Registration Number
- NCT06990880
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 710
- Next
News
GSK Secures $12.5 Billion Deal with Hengrui for COPD Drug and 11 Additional Programs
GSK has entered into agreements with Chinese pharmaceutical company Hengrui worth up to $12.5 billion for exclusive global rights to develop 12 innovative medicines, including a potential best-in-class COPD treatment.
GSK Advances Dostarlimab in Phase 3 Colon Cancer Trial and Phase 2 Endometrial Cancer Study
GSK is conducting a Phase 3 randomized trial evaluating perioperative dostarlimab monotherapy versus standard of care in patients with untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer.
FDA Advisory Panel Rejects GSK's Blenrep Combination Therapies for Multiple Myeloma
FDA advisers voted 5-3 against approving GSK's Blenrep in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma patients.
FDA Advisory Panel Votes Against GSK's Blenrep for Multiple Myeloma Over Eye Safety Concerns
FDA advisers voted that the risks of GSK's blood cancer drug Blenrep outweigh its benefits in treating multiple myeloma, citing serious eye-related side effects as a primary concern.
FDA Raises Eye Safety Concerns for GSK's Blenrep Ahead of Advisory Committee Review
The FDA has identified significant ocular toxicity concerns with GSK's Blenrep (belantamab mafodotin) ahead of a July 17 advisory committee meeting to review the drug's reintroduction to the U.S. market.
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.
Nature Study Validates LIXTE's PP2A Inhibitor LB-100 for Enhanced Cancer Immunotherapy
A Nature study led by MD Anderson researchers found that ovarian cancer patients with PPP2R1A mutations had significantly better overall survival when treated with immune checkpoint blockade therapy.
ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025
ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention.
Hansa Biopharma Appoints Dr. Richard Philipson as Chief Medical Officer to Lead Next Development Phase
Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer effective July 14, bringing over 25 years of industry experience to the commercial-stage biopharmaceutical company.
House Republicans Subpoena Former Pfizer Executive Over Alleged COVID-19 Vaccine Trial Delays
House Judiciary Committee subpoenaed former Pfizer executive Dr. Philip Dormitzer over allegations that senior Pfizer executives deliberately slowed COVID-19 vaccine clinical testing before the 2020 election.